Clinical Trials Logo

Clinical Trial Summary

The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who had never been treated with a complement inhibitor (treatment-naïve).


Clinical Trial Description

The study consisted of a 4-week screening period and a 26-week randomized treatment period (Primary Evaluation Period). After completion of the 26-week Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive ravulizumab for up to 5 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02946463
Study type Interventional
Source Alexion Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 3
Start date December 12, 2016
Completion date February 28, 2023

See also
  Status Clinical Trial Phase
Completed NCT00004143 - Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Phase 2
Terminated NCT05116787 - BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy Phase 2
Recruiting NCT06294301 - A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants Phase 1
Completed NCT03472885 - Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab Phase 2
Completed NCT03946748 - Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Enrolling by invitation NCT03427060 - Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms Phase 2
Completed NCT03078582 - Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Phase 2
Completed NCT03053102 - Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Not yet recruiting NCT06312644 - Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Completed NCT03588026 - Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576 Phase 3
Completed NCT03056040 - ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Phase 3
Completed NCT00145613 - Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies Phase 2
Completed NCT00587054 - Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders Phase 2
Recruiting NCT05876312 - Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Phase 1
Completed NCT04820530 - Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy Phase 3
Terminated NCT03225287 - Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study Phase 2
Completed NCT04558918 - Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment Phase 3
Completed NCT02352493 - A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH Phase 1/Phase 2
Recruiting NCT04901936 - A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Completed NCT02264639 - A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH Phase 1